Table 4.

Safety outcomes within 90 days.

Safety outcomes	Butylphthalide Group (n = 62)	Placebo Group (n = 31)	P
Adverse events—n (%)
Total adverse events	17 (27.4)	5 (16.1)	0.227
Constipation	7 (11.3)	2 (6.5)	0.713
Abnormal liver function	6 (9.7)	0 (0)	0.173
Electrolyte disorder	1 (1.6)	2 (6.5)	0.257
Dizziness and headache	2 (3.2)	1 (3.2)	>0.999
Serious adverse events—n (%)	1 (1.6)	0 (0)	>0.999